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ABSTRACT 
Aristolochic acid (AA) causes aristolochic acid nephropathy, Balkan endemic nephropathy and their 
urothelial malignancies. To identify enzymes involved in the metabolism of aristolochic acid I 
(AAI), the major toxic component of AA we used HRN [Hepatic Cytochrome P450 (Cyp) 
Reductase Null] mice, in which NADPH:Cyp oxidoreductase (Por) is deleted in hepatocytes. AAI 
was demethylated by hepatic Cyps in vitro to 8-hydroxyaristolochic acid I (AAIa), indicating that 
less AAI is distributed to extra-hepatic organs in wild-type (WT) mice. Indeed, AAI-DNA-adduct 
levels were significantly higher in organs of HRN mice, having low hepatic AAI demethylation 
capacity, than in WT mice. Absence of AAI demethylation in HRN mouse liver was confirmed in 
vitro; hepatic microsomes from WT, but not from HRN mice, oxidized AAI to AAIa. To define the 
role of hepatic Cyps in AAI demethylation, modulation of AAIa formation by CYP inducers was 
investigated. We conclude that AAI demethylation is attributable mainly to Cyp1a1/2. The higher 
AAI-DNA adduct levels in HRN than WT mice were the result of the lack of hepatic AAI 
demethylation concomitant with a higher activity of cytosolic NAD(P)H:quinone oxidoreductase 
(Nqo1), which activates AAI. Mouse hepatic Cyp1a1/2 also activated AAI to DNA adducts under 
hypoxic conditions in vitro, but in renal microsomes, Por and Cyp3a are more important than Cyp1a 
for AAI-DNA adduct formation. We propose that AAI activation and detoxication in mice are 
dictated mainly by AAI binding affinity to Cyp1a1/2 or Nqo1, by their turnover and by the balance 
between oxidation and reduction of AAI by Cyp1a. 
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The cytochrome P450 (CYP) superfamily consists of a large number of haem-containing 
mono-oxygenases that play a pivotal role in the metabolism of many drugs and carcinogens (Nebert 
and Dalton, 2006). Vital information on CYP regulation and function has been obtained by in-vitro 
studies, however, for extrapolation from in vitro data to in vivo pharmacokinetics additional factors 
such as route of administration, absorption, renal clearance and tissue-specific CYP expression need 
to be considered (Nebert, 2006). Gene knock-out and transgenic mice have been developed to study 
the role of specific enzymes in drug metabolism (Henderson et al., 2003b). Although knock-out 
mouse models have yielded important data on the effect of single Cyp enzymes on the metabolism 
of drugs and chemical carcinogens (Buters et al., 1999; Kimura et al., 2003; Tsuneoka et al., 2003; 
Uno et al., 2004), the functional redundancy inevitably found in the large CYP family of 
isoenzymes make it difficult to determine the role of CYPs as a whole in the metabolism of 
xenobiotics (Henderson et al., 2006). To overcome these limitations a mouse line, HRN (Hepatic 
Cytochrome P450 Reductase Null), has been developed in which Cyp oxidoreductase (Por), the 
important electron donor to Cyps, is deleted specifically in hepatocytes, resulting in the loss of 
essentially all hepatic Cyp function (Henderson et al., 2003a). The HRN mouse model has been 
used successfully to establish the role of hepatic versus extra-hepatic Cyp-mediated xenobiotic 
metabolism and disposition (Arlt et al., 2005; 2006; 2008; Pass et al., 2005; Stiborová et al., 2008a). 
The herbal drug aristolochic acid (AA) derived from Aristolochia species has been shown to be 
the cause of so-called Chinese herbs nephropathy (CHN), now termed aristolochic acid nephropathy 
(AAN) (Debelle et al., 2008; Schmeiser et al., 2009). The plant extract AA is a mixture of 
structurally related nitrophenanthrene carboxylic acids, the major components being aristolochic 
acid I (AAI; Fig. 1) and aristolochic acid II. AAN is a rapidly progressive renal fibrosis that was 
observed initially in a group of Belgian women who had ingested weight loss pills containing 
Aristolochia fangchi (Vanherweghem et al., 1993). Within a few years of taking the pills, AAN 
patients also developed a high risk of upper urothelial tract carcinoma (about 50%) and, 
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subsequently, bladder urothelial carcinoma (Nortier et al., 2000; Lemy et al., 2008). Subsequently, 
similar cases have been reported elsewhere in Europe and Asia (Lord et al., 2001; Debelle et al., 
2008; Lai et al., 2010). More recently, exposure to AA has been linked to Balkan endemic 
nephropathy (BEN) and its associated urothelial cancer (Arlt et al., 2007; Grollman et al., 2007; 
Nedelko et al., 2009). This nephropathy is endemic in certain rural areas of Serbia, Bosnia, Croatia, 
Bulgaria and Romania. Exposure to AA was demonstrated by the identification of specific AA-
DNA adducts in urothelial tissue of AAN and BEN patients (Schmeiser et al., 1996; Bieler et al., 
1997; Nortier et al., 2000; Lord et al., 2001; Arlt et al., 2002; Grollman et al., 2007). The most 
abundant DNA adduct detected in patients exposed to AA is 7-(deoxyadenosin-N6-yl)-aristolactam 
I (dA-AAI), which leads to characteristic AT→TA transversion mutations. Such AT→TA 
mutations have been observed in the TP53 tumor suppressor gene in tumors from AAN and BEN 
patients (Lord et al., 2004; Arlt et al., 2007; Grollman et al., 2007; Nedelko et al., 2009), indicating 
the probable molecular mechanism of AA carcinogenesis in humans (Simoes et al., 2008; Arlt et al., 
2011). As a consequence, AA was recently classified as carcinogenic to humans (Group 1) by the 
International Agency for Research on Cancer (IARC) (Grosse et al., 2009). 
In common with other nitroaromatics the major activation pathway for AA is nitroreduction 
catalyzed by both cytosolic and microsomal enzymes, cytosolic NAD(P)H:quinone oxidoreductase 
(NQO1) being the most efficient (Stiborová et al., 2002a; 2003a; 2008b; 2011) (Fig. 1). The 
activation of AAI in human hepatic microsomes is mediated by CYP1A2 and, to a lesser extent by 
CYP1A1; POR also plays a minor role (Stiborová et al., 2001b; 2001c; 2005a; 2005c). 
Prostaglandin H synthase (cyclooxygenase, COX) in human renal microsomes has also been shown 
to activate AAI (Stiborová et al., 2001a; 2005a). While the enzymes catalyzing the reductive 
activation of AAI leading to covalent DNA adducts have been widely investigated, those 
participating in its detoxication have not been extensively studied so far. Several studies have 
indicated that induction of Cyp1a (e.g. by 3-methylcholanthrene and ß-naphthoflavone) protect 
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mice from AAI-induced acute renal injury (Xue et al., 2008; Xiao et al., 2008; 2009). One 
detoxication metabolite identified is 8-hydroxy-aristolochic acid I (aristolochic acid Ia, AAIa; Fig. 
1) that is formed after demethylation of AAI and is, in turn, subject to conjugation, forming 
glucuronide or sulfate esters (Krumbiegel et al., 1987; Chan et al., 2007; Shibutani et al., 2010). 
Human CYP1A1 and -1A2 can demethylate AAI to AAIa in vitro (Šístková et al., 2008; Rosenquist 
et al., 2010) and Cyp1a2 in mice appears to mediate this reaction in vivo (Rosenquist et al., 2010). 
Nevertheless, because CYP1A1/2 also activate AAI in human and rat livers (Stiborová et al., 2001a; 
2005a; 2005c; 2008b) detailed knowledge of the catalytic specificities of CYP1A and other CYP 
enzymes in the detoxication and activation of AAI in vitro and in vivo is still lacking. 
The aim of the present study was to evaluate the CYP-mediated oxidative detoxication of AAI. 
We have used the HRN mouse model to examine the hepatic Cyp-dependent metabolism of AAI. 
DNA adduct formation in vivo and in vitro was measured by 32P-postlabelling. In addition, the 
formation of AAIa by human, rat and rabbit hepatic microsomes, and by rat recombinant CYPs was 
determined by high performance liquid chromatography (HPLC).  
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MATERIALS AND METHODS 
Animal treatment 
HRN (Porlox/lox + CreALB) mice on a C57BL/6 background (CXR Bioscience Ltd, Dundee, UK) 
used in this study were derived as described previously (Henderson et al., 2003a). Mice 
homozygous for loxP sites at the Por locus (Porlox/lox) were used as wild-type (WT). Groups of male 
HRN and WT mice (3 months old; 25-30 g; n = 3/group) were treated orally with a single dose of 
10 or 50 mg/kg body weight (bw) of AAI [as sodium salt isolated from the natural mixture of AA 
(38% AAI, 58% AAII; Sigma Chemical Co, St Louis, MO, USA)  by preparative HPLC (Schmeiser 
et al., 1984)] at a concentration of 1 or 5 mg/ml, respectively. Control mice received solvent, water, 
only. Animals were killed 24 h after treatment. Liver, lung, kidney, spleen, colon, small intestine 
and bladder were removed, snap frozen and stored at −80°C until analysis. All procedures were 
carried out under the Animal (Scientific Procedures) Act (1986) in accordance with UK law, and 
following local ethical review.  
 
DNA adduct analysis by 32P-postlabeling 
DNA from tissues was isolated by standard phenol/chloroform extraction. 32P-Postlabelling analysis 
(Phillips and Arlt, 2007) using the nuclease P1 enrichment version, and thin layer chromatography 
(TLC) and HPLC were performed as described (Schmeiser et al., 1996; Bieler et al., 1997). TLC 
sheets were scanned using a Packard Instant Imager (Dowers Grove, USA) and DNA adduct levels 
(RAL, relative adduct labeling) were calculated as described (Schmeiser et al., 1996; Bieler et al., 
1997). Results were expressed as DNA adducts/108 nucleotides.  
 
Preparation of microsomes and cytosols  
Hepatic and renal microsomes and cytosols from HRN and WT mice were isolated as described 
(Stiborová et al., 2003b; 2005a). Hepatic and renal microsomes and cytosols from HRN and WT 
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mice pre-treated (i.p.) with 125 mg/kg bw benzo[a]pyrene (BaP) daily for 5 days were obtained 
from a previous study (Arlt et al., 2008). Pooled microsomal and cytosolic fractions were used for 
further analysis. Male human (pooled sample; cat. no. 452172) and human female hepatic 
microsomes (pooled sample; cat. no. 452183) were from Gentest Corp. (Woburn, MI, USA). 
Microsomes were prepared from livers of ten untreated Wistar rats and three Chinchilla rabbits by 
the procedure described previously (Stiborová et al., 1995; 2002b). Microsomes were also prepared 
from livers of groups of ten Wistar male rats pre-treated with Sudan I, phenobarbital (PB), ethanol 
(EtOH) or pregnenolone-16α-carbonitrile (PCN) as described previously (Stiborová et al., 2002b; 
2003b).  
 
Microsomal incubations used for AAI-DNA adduct analysis  
The deaerated and argon-purged incubation mixtures, in a final volume of 750 µL, consisted of 50 
mM potassium phosphate buffer (pH 7.4), 1 mM NADPH, 1 mg mouse hepatic or renal microsomal 
protein, 0.5 mg calf thymus DNA (2 mM dNp)  and 0.5 mM AAI as described previously 
(Stiborova et al. 2005a). Incubations with microsomes were carried out at 37°C for 60 min and 
AAI-derived DNA adduct formation was found to be linear up to 2 hr (Stiborová et al., 2005a). 
 
Microsomal incubations used for AAI demethylation  
Incubation mixtures, in a final volume of 250 µL, consisted of 100 mM potassium phosphate buffer 
(pH 7.4), 1 mM NADPH, 1 mg human, rat, mouse or rabbit hepatic or mouse renal microsomal 
protein and 10 µM AAI. Incubations with microsomes were carried out at 37°C for 20 min and AAI 
oxidation (demethylation) to AAIa was linear up to 25 min. Control incubations were carried out (i) 
without microsomes, (ii) without NADPH or (iii) without AAI. Supersomes, microsomes isolated 
from insect cells transfected with baculovirus constructs containing cDNA of single rat CYPs 
(CYP1A1, CYP1A2, CYP2A1, CYP2A2, CYP2B1, CYP2C6, CYP2C11, CYP2C12, CYP2C13, 
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CYP2D1, CYP2D2, CYP2E1, CYP3A1, and CYP3A2), and expressing POR and/or cytochrome b5 
were obtained from Gentest Corp and tested for their efficiencies to oxidize AAI. Incubation 
mixtures, in a final volume of 250 µL, consisted of 100 mM potassium phosphate buffer (pH 7.4), 1 
mM NADP+, 10 mM MgCl2, 10 mM D-glucose 6-phosphate, 1 U/mL D-glucose 6-phosphate 
dehydrogenase, to generate NADPH, 50 nM CYPs in Supersomes  and 10 µM AAI. Supersomes 
containing POR alone were used for control.  
 
Determination of AAIa by HPLC  
AAI and its metabolites (i.e. AAIa) were extracted from incubation mixtures twice into ethyl acetate 
(2 × 1 mL), the extracts were evaporated to dryness and the residues redissolved in 30 µL of 
methanol and subjected to reverse-phase HPLC. HPLC was performed with a reversed phase 
column (Nucleosil 100-5 C18, 25 × 4.0 mm, 5 mm; Macherey-Nagel) preceeded by a C-18 guard 
column, using a linear gradient of acetonitrile (20-60% acetonitrile in 55 min) in 100 mM 
triethylamonium acetate with a flow rate of 0.6 mL/min. HPLC was carried out with a Dionex 
HPLC pump P580 with UV/VIS UVD 170S/340S spectrophotometer detector set at 254 nm, and 
peaks were integrated with CHROMELEON™ 6.01 integrator. A product of AAI metabolim and 
AAI itself eluted with retention times (r.t.) of 28.3 and 36 min, respectively. The product eluting at 
28.3 min was identified as AAIa using mass-spectroscopy analyses. Mass spectra were measured on 
MALDI-TOF/TOF ultraFLEX III mass spectrometers (Bruker-Daltonics, Bremen, Germany). 
Positive spectra were calibrated externally using the monoisotopic [M+H]+ ions of PepMixII 
calibrant (Bruker-Daltonics, Bremen) or matrix peaks. A 10 mg/mL solution of α-cyano-4-hydroxy-
cinnamic acid, or 50 mg/mL solution of 2,5-dihydrobenzoic acid in 50% MeCN/0.1% TFA were 
used as MALDI matrix. A 0.5 µL sample dissolved in MeCN was directly mixed with 0.5 µL of the 
matrix solution and allowed to dry at ambient temperature on the target. For NALDI experiments, a 
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1−µL sample dissolved in MeCN was allowed to dry at ambient temperature on NALDI target. The 
MALDI- or NALDI-TOF positive spectra were collected in reflector mode. 
 
Cytosolic incubations used for AAI-DNA adduct analysis  
The deaerated and argon-purged incubation mixtures, in a final volume of 750 µL, consisted of 50 
mM Tris-HCl buffer (pH 7.4), containing 0.2% Tween 20, 1 mM NADPH, 1 mg murine hepatic or 
renal cytosolic protein, 0.5 mg calf thymus DNA (2 mM dNp) and 0.5 mM AAI as described 
previously (Stiborova et al., 2003a). Incubations with human cytosols were carried out at 37°C for 
60 min and AAI-derived DNA adduct formation was found to be linear up to 2 hr (Stiborová et al., 
2003a).  
 
Inhibition studies  
α-Naphthoflavone (α-NF), which inhibits Cyp1a1 and -1a2 (Stiborová et al., 2001b; 2005c); 
ellipticine (E), which competes with Cyp1a1 substrates, thus inhibiting Cyp1a1-mediated oxidation 
of other substrates (Stiborová et al., 2003b; 2004); furafylline (FF), which inhibits Cyp1a2 
(Stiborová et al., 2001b); ketoconazole (KC), which inhibits Cyp3a4 (Stiborová et al., 2001b); and 
α-lipoic acid (α-LA), which inhibits Por (Arlt et al., 2003; Stiborová et al., 2005b) were used to 
inhibit the activation of AAI in murine microsomes. Dicoumarol was used to inhibit the activation 
of AAI by Nqo1 in mouse hepatic cytosols. The inhibition studies were performed as described 
(Stiborová et al., 2001b ; 2003a; Arlt et al., 2005).  
 
Determination of NQO1activity and protein levels by Western blotting  
NQO1 antibodies were prepared as described previously (Stiborová et al., 2002b; 2005b; 2006). 
Immunoquantitation of cytosolic NQO1 was carried out by sodium dodecyl sulfate (SDS)-
polyacrylamide gel electrophoresis (Stiborová et al., 2006). Human recombinant NQO1 (Sigma) 
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was used to identify the band Nqo1 in murine cytosols. NQO1 activity was measured essentially as 
described by Ernster (1976), but the method was improved by addition of cytochrome c 
(Mizerovská et al., 2011).   
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RESULTS 
DNA adduct formation by AAI in HRN mice 
In order to evaluate the role of hepatic Por-dependent Cyp enzymes in the detoxication of AAI 
in vivo we treated HRN and WT mice with a single dose of 10 or 50 mg/kg bw of AAI by oral 
gavage. The formation of AAI-DNA adducts in various organs (liver, lung, kidney, spleen, colon, 
small intestine and urinary bladder) was determined by 32P-postlabeling. Essentially the same DNA 
adduct pattern as that found in vivo in humans (Schmeiser et al., 1996; Bieler et al., 1997) and rats 
(Schmeiser, et al., 1988; Stiborová et al., 1994) and in incubations using rat and human hepatic 
microsomes (Stiborová et al., 2001b, 2005a) and human hepatic and renal cytosols (Stiborová et al., 
2003a), was observed in all tissues analyzed (see Figure 1 inset for kidney of mice treated with 50 
mg/kg bw AAI). Adducts were indentified to be 3´,5´-bisphospho-7-(deoxyguanosin-N2-yl)-
aristolactam I (dG-AAI, spot 1), 3´,5´-bisphospho-7-(deoxyadenosin-N6-yl)-aristolactam I (dA-
AAI, spot 2) and 3´,5´-bisphospho-7-(deoxyadenosin-N6-yl)-aristolactam II (dA-AAII, spot 3) (Pfau 
et al., 1990; Stiborová et al., 1994; Schmeiser et al., 1996; Fig. 1). The identities of the individual 
AAI-derived DNA adducts were confirmed by cochromatographic analysis on TLC and HPLC as 
described previously (Schmeiser et al., 1996) (data not shown). No DNA adducts were observed in 
DNA isolated from the tissues of control animals (data not shown). 
AAI-DNA adduct formation was concentration-dependent and organ-specific (Fig. 2 and 
Supplementary Table S1). Adduct levels in WT mice were highest in the small intestine, followed 
by liver, colon, bladder, lung, spleen and kidney, where adducts were only observed after 50 mg/kg 
(Fig. 2B). In HRN mice treated with either AAI dose higher levels of AAI-DNA adducts were 
found than in WT mice in all organs analyzed, with the highest levels and largest differences in 
kidney (Fig. 2B). The latter finding indicates that the lack of Por-dependent Cyp-mediated 
detoxication of AAI in liver of HRN mice increased the effective concentration of AAI in this organ 
and in extra-hepatic tissues.  
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Human, mouse, rat and rabbit hepatic microsomes oxidize AAI to AAIa 
In-vitro experiments were performed to further examine the role of the mouse hepatic Cyps in 
the detoxication of AAI.  Microsomes were isolated from livers of HRN and WT mice, either 
untreated or pretreated with BaP (i.e. HRN-BaP and WT-BaP mice, Arlt et al., 2008).  For 
comparison, human, rabbit and rat hepatic microsomes were utilized.  
Hepatic microsomes of WT, WT-BaP and HRN-BaP mice were capable of metabolizing AAI 
to one metabolite detectable by HPLC analysis (see peak with r.t. of 28.3 min in Figure 3 for 
microsomes of WT mice). MS (NALDI- and MALDI-TOF-TOF, Fig. 4) was used to identify the 
structure of this metabolite. Negative NALDI-TOF-TOF MS detected a peak at m/z 325.803 (Fig. 
4A), representing the molecular ion [M-H]- of 8-hydroxy-aristolochic acid (AAIa) (for structure see 
Figure 1). Positive MALDI-TOF-TOF detected peaks at m/z 328.043 and 327.029, representing the 
molecular ions [M-H]+ and [M]+ of AAIa, respectively (Fig. 4B). The peaks at m/z 283.021 and 
311.031, representing ions of AAIa fragments, were also found (Fig. 4B). These results show that 
the detected metabolite is the demethylation product of AAI, 8-hydroxy-aristolochic acid (AAIa) 
(for structure see Figure 1), which was found to be a detoxication metabolite of AAI (Shibutani et 
al., 2010). In contrast to hepatic microsomes of WT, WT-BaP and HRN-BaP mice, microsomes of 
HRN mice did not oxidize AAI (Figs. 3C and 5A). Pretreatment of mice with BaP, a potent 
CYP1A1/2 inducer (Arlt et al., 2008) greatly stimulated AAI demethylation to AAIa. Even hepatic 
microsomes of HRN mice treated with BaP were capable of demethylating AAI (Fig. 5A). These 
results correlated well with the protein expression of Cyp1a1/2 and the EROD activity in the 
hepatic microsomes (Arlt et al., 2008; compare Fig. 5B).  
In contrast to mouse hepatic microsomes, renal microsomes from WT and HRN mice did not 
oxidize AAI to AAIa under the same experimental conditions (data not shown). 
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The efficiency of hepatic microsomes from WT mice to form AAIa was compared to that of 
human, rat and rabbit hepatic microsomes (Supplementary fig. S1). Hepatic microsomes from all 
these species oxidized AAI to AAIa. Whereas human and rat hepatic microsomes oxidized AAI 
with similar efficiency, a 1.3-fold lower oxidation of AAI was found in mouse hepatic microsomes 
compared to human microsomes and even lower activity in microsomes of rabbits (Supplementary 
fig. S1).  
The capacity of different CYPs to demethylate AAI to AAIa was studied using hepatic 
microsomes of rats treated with CYP inducers. As shown in Figure 6A, hepatic microsomes of rats 
treated with Sudan I (which induces CYP1A) and PB (which induces CYP2B and -2C) were 1.3 
and 1.1 times more efficient to oxidize AAI to AAIa than uninduced microsomes. In contrast, other 
CYP inducers such as ethanol (which induces CYP2E1) and PCN (which induces CYP3A) 
decreased AAIa formation. Collectively, these findings strongly suggest that CYP1A1/2 enzymes 
are predominantly responsible for AAI demethylation to AAIa in mouse and rat liver microsomes. 
 
Oxidation of AAI to AAIa by rat recombinant CYPs in SupersomesTM 
Further experiments were conducted using microsomes of Baculovirus transfected insect cells 
(SupersomesTM) containing recombinantly expressed rat CYPs, POR and/or cytochrome b5 (Fig. 
6B). Only rat CYPs could be utilized as SupersomesTM containing individual mouse Cyps are not 
available. Rat CYP1A2 was the most efficient enzyme at demethylating AAI to AAIa, followed by 
CYP1A1 (Fig. 6B). Rat recombinant CYP2C enzymes were also capable of demethylating AAI, but 
to a lesser extent (Fig. 6B). No AAIa formation occurred in control incubations with SupersomesTM 
containing POR alone. 
 
Hepatic microsomes of WT, WT-BaP and HRN-BaP but not of HRN mice activate AAI to species 
forming DNA adducts  
 14
In order to evaluate the role of Por-dependent Cyp-mediated activation of AAI in DNA adduct 
formation, we carried out in-vitro incubations using the same hepatic mouse microsomes as those 
used in the experiments above, except that incubations were performed under hypoxic conditions. 
Incubation mixtures were purged with a stream of argon for 3 min before the addition of AAI. 
Although most of the oxygen was removed, we cannot exclude its presence in the membranes and 
lumen of microsomes present in the mixtures. AAI was activated by hepatic microsomes of WT, 
WT-BaP and HRN-BaP mice, generating the same cluster of 3 DNA adducts as those obtained in 
vivo in mice (spots 1, 2 and 3 shown in Figure 1), identified to be dG-AAI (spot 1), dA-AAI (spot 
2) and dA-AAII (spot 3). Pretreatment of mice with BaP increased the levels of AAI-DNA adducts 
catalyzed by hepatic microsomes of both WT and HRN mice (Figs. 5C and 7C and Supplementary 
Table S2). Because this increase corresponded to an increase in Cyp1a1/2 protein expression and 
their enzymatic activities (Arlt et al., 2008; compare Figure 5B), our findings indicate that mouse 
Cyp1a1/2 participate in the metabolic activation of AAI to form DNA adducts. Control incubations 
carried out in parallel without microsomes, or without DNA, or without AAI, were free of adduct 
spots in the region of interest (data not shown). Renal microsomes of both mouse strains (WT and 
HRN) also activated AAI to form the same AAI-DNA adducts, both with similar efficiencies. 
However, renal microsomes of WT mice were less effective than hepatic microsomes (Fig. 7A, 7B 
and Supplementary Tables S2 and S3).  
Whereas hepatic microsomes of WT, WT-BaP and HRN-BaP mice activate AAI to species 
forming DNA adducts, those of HRN mice were not active (Figs. 5C and 7). This finding that again 
parallels Cyp1a1/2 enzyme activity (EROD) (Fig. 5B) might be caused either by the lack of Por-
mediated or Por-dependent-Cyp1a1/2-mediated activation of AAI.  
To further investigate the role of Por-dependent-Cyp-mediated DNA adduct formation by AAI 
in mouse hepatic microsomes, inhibitors of several Cyps and Por were utilized. In hepatic 
microsomes AAI-DNA adduct formation was inhibited with α-NF (which inhibits Cyp1a1/2), 
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ellipticine (which inhibits Cyp1a1) and furafylline (which inhibits Cyp1a2), but not with 
ketoconazole (which inhibits Cyp3a) and α-lipoic acid (which inhibits Por) (Fig. 7A and 7C and 
Supplementary Table S4).  These results corroborate the suggestion that Cyp1a enzymes play an 
important role in AAI-DNA adduct formation in mouse liver, whereas participation of Por or other 
Cyps such as Cyp3a is negligible in this process. The major role of mouse hepatic microsomal 
Cyp1a1/2 in AAI activation is in accordance with former findings showing participation of these 
enzymes in this process in human and rat hepatic microsomes (Stiborová et al., 2001b; 2005a; 
2005c). 
In contrast to hepatic microsomes, AAI-DNA adduct formation catalyzed by renal microsomes 
was inhibited by ketoconazole and α-lipoic acid, but not by α-NF, ellipticine or furafylline (Fig. 7B 
and Supplementary Table S5). An increase in AAI-DNA adduct levels was even produced by α-NF, 
the compound known to stimulate oxidation of several substrates catalyzed by Cyps of the 3a 
subfamily (Rendic and DiCarlo, 1997; Ueng et al., 1997; Bořek-Dohalská et al., 2001; Bořek-
Dohalská and Stiborová, 2010). Moreover, α-NF was also found to stimulate reduction of some 
substrates by POR including AAI, thereby increasing levels of AAI-DNA adducts (Stiborová et al., 
2001b; 2005a; Hodek et al., 2009). Therefore, these results indicate that Cyp3a and Por might 
participate in AAI-DNA adduct formation in mouse kidney. 
Whereas POR was found to catalyze AAI-DNA adduct formation in human kidney microsomes 
(Stiborová et al., 2005a), human CYP3A4, the most abundant CYP enzyme in human livers (Rendic 
and diCarlo, 1997), was inactive (Stiborová et al., 2001b; 2005a; 2005c). Human recombinant 
CYP3A5, the enzyme that is expressed in human kidney, was tested in this work to investigate its 
potential to activate AAI. As shown in Supplementary figure 2 and Supplementary Table S6, 
CYP3A5 expressed in SupersomesTM increases levels of AAI-derived DNA adducts when 
incubated with DNA in vitro, indicating its role in the activation process. This conclusion was also 
supported by the inhibition of AAI-DNA adduct formation in this system by ketoconazole.  
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Metabolic activation of AAI mediated by mouse hepatic and renal cytosols in vitro  
In initial experiments, we investigated the efficiency of hepatic and renal cytosolic samples of 
WT and HRN mice to generate adduct forming species from AAI. Incubations were carried out in 
the presence of NADPH, a cofactor of Nqo1, the enzyme shown to be most efficient in AAI 
activation (Stiborová et al., 2002a; 2003a; 2011). Similarly to human hepatic and renal cytosols 
(Stiborová et al., 2003a; 2011), cytosols of both organs and of both mouse strains were capable of 
activating AAI to form DNA adducts (see Fig. 8A and Supplementary Table S7 for hepatic cytosols 
and Supplementary Table S8 for renal cytosols), but mouse renal cytosols were less effective than 
hepatic cytosols (Supplementary Tables S7 and S8). Interestingly, hepatic cytosolic samples of 
HRN mice were more than 3-fold more efficient in activating AAI to DNA adducts than those of 
WT mice (Fig. 8A and Supplementary Table S7).  
In hepatic cytosols, we also tested whether pretreatment of WT and HRN mice with BaP, a 
Nqo1 inducer (Elovaara et al., 2007; Hockley et al., 2007; Vondráček et al., 2009), influences the 
formation of AAI-DNA adducts. Indeed, more than 3- and 6-fold higher levels of AAI-DNA 
adducts catalyzed by hepatic cytosols of HRN-BaP and WT-BaP mice than untreated mice were 
determined, respectively (Fig. 8A and Supplementary Table S7). This was paralleled by an increase 
in Nqo1 protein expression and enzyme activity in these samples (Fig. 8B and 8C). These results 
demonstrate that Nqo1 plays an important role in livers of both WT and HRN mice, analogous to its 
role in human and rat liver cytosols (Stiborová et al.., 2002a; 2003a; 2011). Indeed, participation of 
Nqo1 in AAI-DNA adduct formation with mouse hepatic cytosols was confirmed by the effect of 
dicoumarol, an Nqo1 inhibitor, in reducing DNA binding (Supplementary fig. 3 and Supplementary 
Table S9).  
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DISCUSSION 
A large body of evidence indicates that metabolic activation and detoxication of AAI influences 
its nephrotoxic and carcinogenic effects. Demethylation of AAI to AAIa is believed to be 
detoxication reaction, because AAIa was found to be much less toxic than AAI (Shibutani et al., 
2010). In addition, AAIa or its conjugates, the glucuronide, the acetate and the sulfate esters, are 
readily excreted in urine (Chan et al., 2006; 2007).  
Formation of AAIa was recently found to be catalyzed mainly by human CYP1A1 and -1A2 in 
vitro (Šístková et al., 2008; Rosenquist et al., 2010) and by mouse Cyp1a2 in vivo (Rosenquist et 
al., 2010). However, CYP1A1 and -1A2 are the enzymes that also activate AAI (Stiborová et al., 
2001b; 2005a; 2005c). We therefore investigated participation of these and other CYPs both in 
detoxication and in activation of AAI in detail.  
HRN mice carry a deletion of the Por gene in hepatocytes (Henderson and Wolf, 2003; 
Henderson et al., 2003b), and thus lack Cyp activity in the liver. AAI-DNA adducts were formed in 
all organs of both WT and HRN mice treated with AAI. These findings suggest that AAI is 
distributed via the blood stream to other organs and that these tissues have the metabolic capacity to 
reductively activate this carcinogen. Moreover, our results demonstrate that Por-dependent, Cyp-
mediated metabolism of AAI in the liver dictates the formation of DNA adducts by this compound 
also in extrahepatic organs in mice in vivo. Besides such an in vivo study, we performed in-vitro 
experiments utilizing subcellular systems (i.e. microsomes and cytosols) of the liver, the organ that 
is predominantly responsible for the biotransformation of many xenobiotics, as well as the kidney, 
the target organ for AAI toxicity. We demonstrated that hepatic Cyps oxidize AAI, thereby 
decreasing its concentrations in liver of WT mice, and lower amounts of AAI are distributed to 
extra-hepatic organs than in HRN mice. Indeed, lower levels of AAI-DNA adducts were found in 
tissues of WT mice relative to HRN mice. Absence of AAI demethylation activity (i.e. 
detoxication) in livers of HRN mice was also shown by in vitro experiments. Whereas hepatic 
microsomes isolated from WT mice oxidized AAI to AAIa, those from HRN mice were not capable 
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of catalyzing this reaction. These results fit well with the proposed scheme of AAI metabolism (see 
Fig. 1). If AAI is not oxidized to AAIa in the liver, it is activated by several enzymes with 
nitroreductase activity (for a review, see Stiborová et al., 2008b; 2008c) to form a cyclic 
acylnitrenium ion generating DNA adducts (Fig. 1). Our results are in accordance with another 
study showing that mice that lack hepatic Por-dependent Cyp activity (also HRN mice, but a 
different strain) are extremely sensitive to AA toxicity (Xiao et al., 2008). Together with the present 
study, these results demonstrate that the HRN mouse model used in the study is an excellent model 
not only to further investigate the toxic effects of AAI, but also of other toxic agents. 
We found that the hepatic CYP enzymes of the 1A subfamily of mice and rats are crucial for in 
vitro demethylation of AAI in rodents, similar to its role in human systems (Šístková et al., 2008; 
Rosenquist et al., 2010). Inducers of these enzymes such as BaP (Arlt et al., 2008) and Sudan I 
(Stiborová et al., 2002b) increased demethylation of AAI catalyzed by mouse and rat hepatic 
microsomes. The results found in in-vitro experiments using mouse hepatic microsomes correspond 
well to the situation in vivo; as shown by Rosenquist and co-workers (2010), treatment of mice 
lacking Cyp1a2 protein expression (Cyp1a2 knockout mice) with AAI led to elevated levels of 
AAI-DNA adducts in the renal cortex and to an increase in microalbuminuria, an indicator of renal 
tubule dysfunction, relative to WT mice. A major role of CYP1A in AAI demethylation was also 
confirmed in the present work by utilizing rat recombinant CYP enzymes; rat CYP1A2, followed 
by CYP1A1, were the most efficient in AAI demethylation to AAIa. In addition to rat CYP1A1/2, 
rat CYP enzymes of the 2C subfamily were also capable of demethylating AAI, but with much 
lower efficiencies than CYP1A. But because CYP2C enzymes in rat hepatic microsomes constitute 
55% of all CYP, while CYP1A only 2% (Nedelcheva and Gut, 1994; Rolsted and Kissmeyer, 
2008), the contributions of CYP2C enzymes to AAI demethylation in rat livers might be important.  
The increase in AAI-DNA adduct formation found in HRN mice is the combined result of the 
lack of AAI detoxication by demethylation catalyzed by hepatic Cyps, and the reductive activation 
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of AAI by Nqo1, the most effective  activating enzyme in human and rat liver and kidney 
(Stiborová et al., 2002a; 2003a; 2011). Expression and activity of this enzyme in the liver of HRN 
mice were higher than in the liver of WT mice. This higher Nqo1 activity results in better activation 
of AAI to DNA adduct formation with hepatic cytosol of HRN mice. Likewise, increased AAI-
DNA adduct formation was found with renal cytosol of HRN mice as compared with WT mice. Of 
note, it was reported that polymorphisms in the human NQO1 gene are important in AAI-induced 
nephropathy [i.e. BEN, a disease that is associated with dietary exposure to AA (Arlt et al., 2007; 
Grollman et al., 2007)] and/or carcinogenicity (Toncheva et al., 2004; Atanasova et al., 2005). 
Indeed, one of the NQO1 polymorphisms, the genotype NQO1*2/*2, was shown to predispose 
patients suffering from BEN to develop urothelial cancer (OR=13.75, 95%CI 1.17-166.21) 
(Toncheva et al., 2004). This finding together with the demonstration of the importance of NQO1 in 
AAI activation could be an explanation for cancer induction by AAI in only some of the AAN and 
BEN patients. The results found in this and former (Stiborová et al., 2002a; 2003a; 2011) studies 
strongly support the hypothesis (Stiborová et al., 2008c) that a key point determining the 
carcinogenic and nephrotoxic effects of AAI lies in the balance of activities of reductases such as 
NQO1, catalyzing AAI-DNA adduct formation, and enzymes such as CYPs, which detoxify AAI to 
AAIa. 
It should be emphasized however that under the hypoxic (anaerobic) conditions, mouse hepatic 
Cyp1a enzymes were also capable of reducing AAI to adduct forming species in vitro. Whereas 
hepatic microsomes of WT mice catalyzed activation of AAI to form AAI-DNA adducts, only 
hepatic microsomes of HRN mice pretreated with BaP, an inducer of Cyp1a, were able to catalyze 
this reaction, but not microsomes from untreated HRN mice. The major role of Cyp1a in AAI-DNA 
adduct formation by hepatic microsomes was also demonstrated using selective inhibitors. 
Inhibitors of Cyp1a1 and -1a2, but not of Por and Cyp3a, decreased levels of AAI-DNA adducts 
formed by hepatic microsomes. These findings demonstrate that besides the levels of Cyp1a 
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expression in the liver, the in vivo oxygen concentration in tissues will affect the balance between 
nitroreduction and demethylation of AAI, thereby influencing its toxicity and carcinogenicity. 
Taking into account all available data, we propose that the pathways of AAI metabolism are mainly 
dictated by the binding affinities of AAI to CYP1A or NQO1, and their enzymatic turnover as well 
as by the balance between the efficiency of CYP1A to oxidize and reduce AAI. 
In contrast to mouse hepatic microsomes, Por and Cyp3a enzymes seem to be more important 
in AAI-DNA adduct formation in renal microsomes. Previously POR was found to be an efficient 
enzyme catalyzing activation of AAI in human kidney (Stiborová et al., 2005a). However, the 
participation of renal mouse Cyp3a in AAI-DNA adduct formation was initially rather surprising, 
because human CYP3A4 that was tested previously for its efficiency to activate AAI was found to 
be ineffective (Stiborová et al., 2005a). CYP3A5, another human enzyme of the CYP3A subfamily, 
predominantly expressed in human kidney, was herein found to activate AAI. This finding might 
explain the results of a pilot genetic study (Atanasova et al., 2005), which found a weak association 
between human CYP3A5*1 allele and BEN.  
In conclusion, although the impact of individual metabolic enzymes on the nephrotoxicity and 
carcinogenicity of AAI is still not entirely resolved, one question was unambiguously answered by 
our present work and other recent studies (Xiao et al., 2008, Rosenquist et al. 2010), namely that 
hepatic Cyp1a enzymes detoxify AAI in mice, thus decreasing its renal toxicity. The evaluation of 
inter-individual variations in the human enzymes that play a major role in AAI activation and 
detoxication, including their genetic polymorphisms, remain a major challenge to explain human 
individual susceptibility to AAI, and to predict the risk of cancer among the AAN and BEN 
patients. 
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Legends for Figures 
FIG. 1. Pathways of biotransformation and DNA adduct formation of AAI. dA-AAI, 7-
(deoxyadenosin-N6-yl)aristolactam I; dG-AAI, 7-(deoxyguanosin-N2-yl)aristolactam I; NR, 
nitroreduction; UGT, UDP glucuronyl transferase; SULT, sulfotransferase. Inset: Autoradiographic 
profile of AA-DNA adducts in kidney of HRN mice treated with 50 mg/kg bw of AAI by using the 
nuclease P1 enrichment version of the 32P-postlabeling assay. The origin, in the bottom left-hand 
corner, was cut off before exposure. Spot 1, dG-AAI; spot 2, dA-AAI; spot 3, 7-(deoxyadenosin-N6-
yl)aristolactam II (dA-AAII).   
FIG. 2. Quantitative TLC 32P-postlabeling analysis of DNA adducts formed by AAI in organs of 
HRN and WT mice treated orally with 10 (A) or 50 mg AAI/kg bw for 24 hours (B). F, fold 
increase in DNA adducts in HRN mice compared with WT mice. RAL, relative adduct labeling. 
ND, not detected. Values are given as means ± SD (n = 3). Values significantly different from WT 
mice: *p<0.05, **p<0.01, ***p<0.001 (Student’s t-test). 
FIG. 3. HPLC chromatograph of AAIa metabolite (peak r.t. at 28.3 min) and AAI (peak r.t. at 36 
min) produced by hepatic microsomes of WT mice incubated with AAI and NADPH (A), by 
hepatic microsomes of WT mice incubated with AAI without NADPH (B) and by hepatic 
microsomes of HRN mice incubated with AAI and NADPH (C). The peaks with the characterized 
AAI metabolite (AAIa) and the parent AAI are indicated in the chromatograms. 
FIG. 4. Identification of AAI metabolite as AAIa. Negative NALDI-TOF/TOF (A) and positive 
MALDI-TOF/TOF (B) of AAIa. The peaks at m/z 348.736 and 366.765 in panel A are matrix 
peaks.  
FIG. 5. Oxidation of AAI to AAIa by murine hepatic microsomes isolated from livers of HRN and 
WT mice, control mice (untreated) or mice pretreated (i.p.) with 125 mg BaP/kg bw daily for 5 days 
(Arlt et al., 2008) (A); Cyp1a enzymatic activity (EROD activity) in hepatic microsomes (B). DNA 
adduct formation by AAI activated with hepatic microsomes as determined by TLC 32P-postlabeling 
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(C). RAL, relative adduct labeling. ND, not detected. All values are given as means ± SD (n = 3). 
Values significantly different from control (untreated) WT mice: ***p<0.001 (Student’s t-test). 
FIG. 6. Oxidation of AAI by rat hepatic microsomes (A) or recombinant CYPs of rat (B). Values 
are given as means ± SD (n = 3). Values significantly different from hepatic microsomes of control 
(untreated) rats: *p<0.05, **p<0.01, ***p<0.001 (Student’s t-test). Sudan I, phenobarbital (PB), 
ethanol (EtOH) and pregnenolone-16α-carbonitrile (PCN) were used as inducers of rat CYPs. 1 mg 
microsomal protein or 50 µM rat recombinant CYPs and 10 µM AAI were used in incubations (see 
Materials and Methods). Control, control SupersomesTM containing POR alone (50 nM). ND, not 
detected. 
FIG. 7. Effect of different inhibitors on DNA adduct formation by AAI activated with hepatic or 
renal microsomes isolated from HRN and WT mice as determined by TLC 32P-postlabeling. 
Hepatic (A) and renal microsomes of control mice (untreated) (B). (C) Hepatic microsomes of mice 
pretreated (i.p) with 125 mg/kg bw BaP daily for 5 days (Arlt et al., 2008). Inhibitors α-NF, α-
naphthoflavone; E, ellipticine; FF, furafylline; KC, ketoconazole; α-LA, lipoic acid were used in 
the experiments. F, fold increase in DNA binding in hepatic or renal microsomes from WT mice 
compared with HRN mice. RAL, relative adduct labeling. Control, without cofactor. ND, not 
detected. Values are given as means ± SD (n = 3). Values significantly different from incubations 
without inhibitors: ***p<0.001 (Student’s t-test). 
FIG. 8. DNA adduct formation by AAI activated with hepatic cytosols isolated from livers of HRN 
and WT mice, control mice (untreated) or mice pretreated (i.p.) with 125 mg/kg bw BaP daily for 5 
days (Arlt et al., 2008) as determined by TLC 32P-postlabeling (A). RAL, relative adduct labeling. 
Nqo1 protein expression in hepatic cytosols as determined by Western blotting (see insert) (B). 
Nqo1 enzymatic activity in hepatic cytosols (C). Human recombinant NQO1 (Sigma; NQO1 stan, 
see insert B) was used to identify the Nqo1 band in murine cytosols. All values are given as means 
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± SD (n = 3). Values significantly different from control (untreated) mice: ***p<0.001 (Student’s t-
test). 
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Figure 4  
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Figure 5 
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Figure 8 
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